- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
- UCSD Moores Cancer Center La Jolla, California, United States
- Loma Linda University Medical Center Loma Linda, California, United States
- Tower Cancer Research Foundation Los Angeles, California, United States
Clinical trial condition
Immunoproliferative Disorders
Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.
9,998 public trials
2,034 recruiting studies
Immunoproliferative Disorders trial results
NCT01165112
- Conditions
- Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +11 more
- Locations
-
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
NCT00923520
- Conditions
- Adenocarcinoma, Breast Cancer, Breast Diseases, +43 more
- Locations
-
- National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
- Hershey Medical Center Hershey, Pennsylvania, United States
- University of Pittsburgh Pittsburgh, Pennsylvania, United States
NCT01701700
- Conditions
- Eye Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
- Locations
-
- Manchester Royal Eye Hospital Manchester, United Kingdom
NCT01200758
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
- Locations
-
- Gosford Hospital; Cancer Care Services Gosford, New South Wales, Australia
- Wollongong Hospital; Cancer Services Wollongong, New South Wales, Australia
- Royal Brisbane and Women's Hospital Herston, Queensland, Australia
- Gold Coast Hospital; Haematology Department Southport, Queensland, Australia
NCT01401530
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Nagoya, Aichi-ken, Japan
- Kashiwa, Chiba, Japan
- Isehara, Kanagawa, Japan
- Chuo-ku, Tokyo, Japan
Completed
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
NCT00860457
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
- Locations
-
- Lombardi Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
NCT01470196
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
NCT03255668
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
- Locations
-
- Cipto Mangunkusomo hospital Jakarta Pusat, Jakarta Special Capital Region, Indonesia
NCT00295932
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +27 more
- Locations
-
- Winship Cancer Institute of Emory University Atlanta, Georgia, United States
- Memorial Sloan-Kettering at Basking Ridge Basking Ridge, New Jersey, United States
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States
- Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York, United States